logo
  

Genentech's Subcutaneous Formulation Of Tecentriq Shows Positive Results In Phase III Study

Roche's Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq or atezolizumab with Halozyme's ENHANZE technology met its co-primary endpoints, Genentech, a member of the Roche Group (RHHBY), and Halozyme Therapeutics Inc. (HALO) said in a statement.

The companies stated that the study showed non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with intravenous (IV) infusion, in cancer immunotherapy-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) for whom prior platinum therapy has failed.

The safety profile of the subcutaneous formulation was consistent with that of IV Tecentriq.

Halozyme noted that the positive results further demonstrated the opportunity for a coformulation of ENHANZE to potentially benefit patients by reducing the treatment time of Tecentriq to 3-8 minutes as a subcutaneous delivery from 30-60 minutes for IV treatment.

Multiple oncology studies suggest that the majority of cancer patients generally prefer to receive treatment subcutaneously due to reduced pain and discomfort, ease of administration and shorter duration of treatment, compared to IV infusion.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream Amazon.com Inc. plans to spend more than $1 billion annually to produce movies that will get a theatrical release, Bloomberg reported, citing people familiar with the matter. The online retailer giant, which acquired movie maker MGM Studios earlier this year for $8.45 billion, is likely to produce between 12 and 15 movies each year for movie theaters. New York-based Bentex Group has recalled various children's clothing sets due to violation of the federal lead paint and lead content ban, as well as lead poisoning risk, the U.S. Consumer Product Safety Commission said. The recall involves about 87,000 units of Bentex children's clothing sets in nine different Disney themed styles.
Follow RTT